Trailhead Biosystems, a Beachwood, OH-based biotechnology company which specializes in human cell innovation, raised $20M in funding.
Backers were not disclosed.
The company intends to use the funds to enhance its portfolio of iPSC-derived cells for research applications, advancing preclinical drug discovery and disease modeling.
Led by CEO, CSO and Founder Jan Jensen, Trailhead Biosystems leverages a proprietary high-dimensional design of experiments (HD-DoE®) platform for regenerative medicine and drug discovery precisely differentiating induced pluripotent stem cells (iPSCs) into functional human cell types.
The company recently introduced TrailBio® Vascular Leptomeningeal Cells (VLMCs) for blood-brain barrier research, addressing a critical need in neuroscience and drug delivery.
Trailhead also has an office in Koendall Square, Cambridge, MA.
FinSMEs
10/05/2025